MCID: VSC008
MIFTS: 43

Vascular Hemostatic Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Hemostatic Disease

MalaCards integrated aliases for Vascular Hemostatic Disease:

Name: Vascular Hemostatic Disease 12 15
Vascular Hemostatic Disorders 74
Hemostatic Disorders 45

Classifications:



External Ids:

Disease Ontology 12 DOID:484
MeSH 45 D020141
SNOMED-CT 69 21112004
UMLS 74 C0600502

Summaries for Vascular Hemostatic Disease

MalaCards based summary : Vascular Hemostatic Disease, also known as vascular hemostatic disorders, is related to thrombophilia due to activated protein c resistance and disseminated intravascular coagulation. An important gene associated with Vascular Hemostatic Disease is KRIT1 (KRIT1 Ankyrin Repeat Containing), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Warfarin and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and b cells, and related phenotypes are cardiovascular system and embryo

Wikipedia : 77 Hemostasis or haemostasis is a process which causes bleeding to stop, meaning to keep blood within a... more...

Related Diseases for Vascular Hemostatic Disease

Diseases related to Vascular Hemostatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 31.4 F3 SERPINC1
2 disseminated intravascular coagulation 29.0 F3 SERPINC1
3 thrombophilia due to protein c deficiency, autosomal dominant 11.0
4 thrombophilia, x-linked, due to factor ix defect 11.0
5 thrombophilia due to protein c deficiency, autosomal recessive 11.0
6 thrombophilia due to protein s deficiency, autosomal dominant 11.0
7 heparin cofactor ii deficiency 11.0
8 thrombophilia due to histidine-rich glycoprotein deficiency 11.0
9 antithrombin iii deficiency 11.0
10 protein z deficiency 11.0
11 thrombophilia due to thrombomodulin defect 11.0
12 intracranial structure hemangioma 10.4 KRIT1 SNRPB
13 brain angioma 10.4 KRIT1 SNRPB
14 cerebral angioma 10.4 KRIT1 SNRPB
15 shwartzman phenomenon 10.2 F12 F3
16 kaposiform hemangioendothelioma 10.2 GNA14 PECAM1
17 hemangioma 10.1 CCM2 KRIT1 PECAM1
18 cerebral cavernous malformations 10.1 CCM2 KRIT1 PDCD10
19 cavernous malformation 10.1 CCM2 KRIT1 PDCD10
20 human venous malformation 10.1 CCM2 KRIT1 PDCD10
21 klippel-trenaunay-weber syndrome 10.1 CCM2 KRIT1 PDCD10
22 venous malformations, multiple cutaneous and mucosal 10.1 CCM2 KRIT1 PDCD10
23 encephalopathy, familial, with neuroserpin inclusion bodies 10.0 PDCD10 SERPINC1
24 intracranial embolism 10.0 F12 SERPINC1
25 leech infestation 10.0 F3 SERPINC1
26 intestinal impaction 10.0 F3 SERPINC1
27 fournier gangrene 10.0 F3 SERPINC1
28 heparin-induced thrombocytopenia 10.0 F3 SERPINC1
29 giant hemangioma 10.0 F3 SERPINC1
30 sagittal sinus thrombosis 10.0 F3 SERPINC1
31 blue toe syndrome 10.0 F3 SERPINC1
32 korean hemorrhagic fever 10.0 F3 SERPINC1
33 marantic endocarditis 10.0 F3 SERPINC1
34 purpura fulminans 9.9 F3 SERPINC1
35 hepatic infarction 9.9 F3 SERPINC1
36 peripheral vertigo 9.9 F3 SERPINC1
37 inherited blood coagulation disease 9.9 F3 SERPINC1
38 blood coagulation disease 9.9 F3 SERPINC1
39 intracranial thrombosis 9.9 F3 SERPINC1
40 cavernous hemangioma 9.9 CCM2 KRIT1 PDCD10 PECAM1
41 blood protein disease 9.9 F3 SERPINC1
42 cerebral cavernous malformations 3 9.9 CCM2 KRIT1 PDCD10 SNRPB
43 central nervous system benign neoplasm 9.9 CCM2 KRIT1 PDCD10 SNRPB
44 branch retinal artery occlusion 9.9 F3 SERPINC1
45 cerebral cavernous malformations 2 9.9 CCM2 KRIT1 PDCD10 SNRPB
46 cell type benign neoplasm 9.9 CCM2 KRIT1 PDCD10 SNRPB
47 intermediate coronary syndrome 9.9 F3 SERPINC1
48 coronary thrombosis 9.9 F3 SERPINC1
49 pulmonary immaturity 9.9 F3 SERPINC1
50 hepatic vascular disease 9.9 F3 SERPINC1

Graphical network of the top 20 diseases related to Vascular Hemostatic Disease:



Diseases related to Vascular Hemostatic Disease

Symptoms & Phenotypes for Vascular Hemostatic Disease

MGI Mouse Phenotypes related to Vascular Hemostatic Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 CCM2 ESAM F3 KRIT1 PDCD10 PECAM1
2 embryo MP:0005380 9.43 CCM2 CR1L F3 KRIT1 PDCD10 SERPINC1
3 hematopoietic system MP:0005397 9.17 CCM2 CR1L ESAM F3 PDCD10 PECAM1

Drugs & Therapeutics for Vascular Hemostatic Disease

Drugs for Vascular Hemostatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 844)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 54678486 6691
2
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 460612 4053
3
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
10
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
11
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1197-18-8 5526
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
13
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 6473866 445643 439492
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
19
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6 46507594 772
21
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
22
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
23
Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
24
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
25
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
26
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
27
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
28
Apixaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 503612-47-3 10182969
29
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
30 Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
31
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
32
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
33 fluindione Approved, Investigational Phase 4 957-56-2
34
Phenindione Approved, Investigational Phase 4 83-12-5 4760
35
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84-80-0
36 Menaquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1182-68-9
37
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
38
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
39
Celiprolol Approved, Investigational Phase 4 56980-93-9
40
Phentolamine Approved Phase 4 50-60-2 5775
41
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
42
Protein C Approved Phase 4,Phase 3
43
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
44
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
45
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
46
Edoxaban Approved Phase 4,Phase 2,Phase 3 480449-70-5
47
Ketorolac Approved Phase 4,Phase 3 74103-06-3, 66635-83-4 3826
48
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
49
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
50
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-45-1 5951

Interventional clinical trials:

(show top 50) (show all 3020)
# Name Status NCT ID Phase Drugs
1 Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
2 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
3 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
4 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
5 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
6 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
7 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
8 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
9 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes Completed NCT00738023 Phase 4 Rosiglitazone;Normal saline 0.9%;Intralipid 20%
10 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
11 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
12 Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
13 Octaplas Pediatric Plasma Replacement Trial Completed NCT02050841 Phase 4
14 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
15 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
16 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
17 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period Completed NCT03449342 Phase 4 turoctocog alfa
18 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
19 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
20 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
21 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
22 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
23 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
24 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
25 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
26 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
27 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
28 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
29 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
30 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
31 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
32 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
33 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
34 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
35 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
36 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
37 Fibrinogen Concentrate In Children Cardiac Surgery 2 Recruiting NCT03884725 Phase 4 Fibrinogen Concentrate
38 Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
39 Human Fibrinogen Concentrate in Pediatric Cardiac Surgery Recruiting NCT02822599 Phase 4 RiaStAP;Saline
40 Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal Recruiting NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
41 CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients Recruiting NCT02777424 Phase 4 Prothrombin Complex Concentrate
42 RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
43 STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
44 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
45 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
46 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
47 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
48 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
49 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
50 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide

Search NIH Clinical Center for Vascular Hemostatic Disease

Cochrane evidence based reviews: hemostatic disorders

Genetic Tests for Vascular Hemostatic Disease

Anatomical Context for Vascular Hemostatic Disease

MalaCards organs/tissues related to Vascular Hemostatic Disease:

42
T Cells, Bone Marrow, B Cells, Testes, Kidney, Myeloid, Nk Cells

Publications for Vascular Hemostatic Disease

Articles related to Vascular Hemostatic Disease:

(show all 14)
# Title Authors Year
1
Hemostatic Disorders in Hormonally Active Pituitary Tumors. ( 26285071 )
2015
2
Effects of transcutaneous aortic valve implantation on aortic valve disease-related hemostatic disorders involving von Willebrand factor. ( 25935884 )
2015
3
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. ( 24951423 )
2014
4
[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]. ( 21574459 )
2011
5
Hemostatic disorders in type 1 diabetes mellitus. ( 21249604 )
2011
6
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. ( 19684626 )
2009
7
Hemostatic disorders in bird flu infection. ( 18180608 )
2008
8
Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. ( 18001734 )
2008
9
[Recurrent epistaxis in children as an indicator of hemostatic disorders]. ( 9949588 )
1998
10
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]. ( 9499627 )
1998
11
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. ( 8522567 )
1995
12
[The Willebrand factor in the diagnosis of hemostatic disorders in patients with rheumatoid arthritis]. ( 1710721 )
1991
13
Desmopressin for diabetes insipidus, hemostatic disorders and enuresis. ( 2220513 )
1990
14
[Characteristics of hemostatic disorders in septic shock in children]. ( 2396772 )
1990

Variations for Vascular Hemostatic Disease

Expression for Vascular Hemostatic Disease

Search GEO for disease gene expression data for Vascular Hemostatic Disease.

Pathways for Vascular Hemostatic Disease

GO Terms for Vascular Hemostatic Disease

Biological processes related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.43 KRIT1 PDCD10 PECAM1
2 blood coagulation GO:0007596 9.33 F12 F3 SERPINC1
3 regulation of blood coagulation GO:0030193 8.96 F12 SERPINC1
4 hemostasis GO:0007599 8.8 F12 F3 SERPINC1

Sources for Vascular Hemostatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....